Compare · ABBV vs PEPG
ABBV vs PEPG
Side-by-side comparison of AbbVie Inc. (ABBV) and PepGen Inc. (PEPG): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABBV and PEPG operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ABBV is the larger of the two at $501.19B, about 1352.9x PEPG ($370.4M).
- Over the past year, ABBV is up 23.6% and PEPG is down 26.3% - ABBV leads by 49.8 points.
- ABBV has been more active in the news (17 items in the past 4 weeks vs 12 for PEPG).
- ABBV has more recent analyst coverage (25 ratings vs 6 for PEPG).
- Company
- AbbVie Inc.
- PepGen Inc.
- Price
- -
- -
- Market cap
- $501.19B
- $370.4M
- 1M return
- -0.38%
- +39.26%
- 1Y return
- +23.56%
- -26.27%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2012
- 2022
- News (4w)
- 17
- 12
- Recent ratings
- 25
- 6
AbbVie Inc.
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production. The company was incorporated in 2012 and is based in North Chicago, Illinois.
PepGen Inc.
PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. The company's lead product candidate is PGN-EDO51, an EDO peptide in Phase I clinical trials to treat individuals with Duchenne muscular dystrophy (DMD). It is also developing PGN-EDODM1, an EDO peptide-conjugated PMO for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. The company was founded in 2018 and is headquartered in Cambridge, Massachusetts.
Latest ABBV
- AbbVie to Present at the Piper Sandler 38th Annual Healthcare Conference
- EVP, CHIEF OPERATIONS OFFICER Azita Saleki exercised 23,935 shares at a strike of $61.36 and covered exercise/tax liability with 13,481 shares, increasing direct ownership by 5% to 208,248 units (SEC Form 4)
- EVP, CHIEF COMMERCIAL OFFICER Stewart Jeffrey Ryan exercised 40,619 shares at a strike of $101.75, sold $11,925,738 worth of shares (40,619 units at $293.60) and gifted 3,450 shares, decreasing direct ownership by 4% to 79,721 units (SEC Form 4)
- Allergan Aesthetics Reports Improved Satisfaction With Facial Appearance Following Aesthetic Treatment in Two Studies of Patients on GLP-1 Medications
- SEC Form 10-Q filed by AbbVie Inc.
- Allergan Aesthetics to Present New Research on Aesthetic Care Following Medical Weight Loss and Evolving Patient Needs at ASDS 2026
- AbbVie Inc. filed SEC Form 8-K: Leadership Update
- Brise Pharmaceuticals Announces Global License Agreement with AbbVie to Advance the Next-Generation of Migraine Therapies
- AbbVie Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- AbbVie Reports Third-Quarter 2026 Financial Results
Latest PEPG
- Amendment: SEC Form SCHEDULE 13D/A filed by PepGen Inc.
- Director Ra Capital Management, L.P. bought $43,125,000 worth of shares (8,625,000 units at $5.00) (SEC Form 4)
- PepGen Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits
- SEC Form 424B5 filed by PepGen Inc.
- PepGen Announces Pricing of $125 Million Public Offering
- SEC Form 424B5 filed by PepGen Inc.
- PepGen Announces Proposed $125.0 Million Public Offering of Common Stock
- PepGen upgraded by BofA Securities with a new price target
- PepGen Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- SEC Form 10-Q filed by PepGen Inc.